UK - English
Select a Country

MEDIA ROOM

The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

For media-related inquiries, please use the following email address:

UKMediaRelations@abbvie.com

and your inquiry will be directed to the appropriate media relations person at AbbVie. If your matter is urgent, please call +44 (0)1628 925 200 and ask to speak to the AbbVie UK Communications Team.


file

'Fear of Finding Out' Makes up a Third of Conscious Reasons Why We Don't Visit The Doctor

30 January 2017

Read full press release »


file

European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorisation Application for AbbVie’s Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

24 January 2017

Read full press release »


file

AbbVie’s HUMIRA® (Adalimumab) Approved by European Commission to Treat Adolescents with Hidradenitis Suppurativa (HS)

16 December 2016

Read full press release »


file

New Oral Therapy VENCLYXTO®▼ (venetoclax) Receives Marketing Authorisation For Patients With Difficult-To-Treat, Chronic Lymphocytic Leukaemia, The Most Common Form Of Adult Leukaemia 

8 December 2016

Read full press release »


file

The Macmillan Occupational Therapy Team at Heart of England Foundation Trust named as winner of AbbVie’s inaugural Sustainable Healthcare ‘Patients as Partners’ Award

29 November 2016

Read full press release »


file

Central Manchester University Hospitals NHS Foundation Trust named as winner of AbbVie’s inaugural Sustainable Healthcare ‘Patients as Partners’ Award

29 November 2016

Read full press release »


file

Tyneside Occupational Therapy team named as winner of AbbVie’s inaugural Sustainable Healthcare ‘Patients as Partners’ Award 

29 November 2016

Read full press release »


file

UK Teenagers Lack Access to Health Education and NHS Awareness, says Sustainable Healthcare Poll 

29 November 2016

Read full press release »


file

AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

15 November 2016

Read full press release »


file

Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes of Chronic Hepatitis C

11 November 2016

Read full press release »


file

AbbVie receives CHMP positive opinion for Venclyxto™ (venetoclax) tablets for appropriate patients with difficult-to-treat chronic lymphocytic leukaemia 

14 October 2016

Read full press release »


file

AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C

23 September 2016

Read full press release »


file

AbbVie’s Venetoclax Receives EAMS Positive Scientific Opinion in Chronic Lymphocytic Leukaemia (CLL) from the MHRA in the UK, first in any blood cancer for the scheme

23 August 2016

Read full press release »


file

Lancet publication: Visual II Study Shows Humira®(adalimumab) Lowers Risk of Uveitic Flare by 43% in Patients with Inactive Non-Infectious Uveitis Requiring Corticosteroids

18 August 2016

Read full press release »


file

CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) 

25 July 2016

Read full press release »


file

AbbVie’s HUMIRA® (adalimumab) Now Approved by the European Commission to Treat Certain Forms of Non-Infectious Uveitis, A Disease That Can Severely Impact Vision 

5 July 2016

Read full press release »


file

AbbVie’s HUMIRA® (adalimumab) Now Approved by the European Commission to Treat Certain Forms of Non-Infectious Uveitis, A Disease That Can Severely Impact Vision 

5 July 2016

Read full press release »


file

New guidance from NICE recommends Humira® (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition

22 June 2016

Read full press release »


file

Venetoclax, a novel B-cell lymphoma-2 (BCL-2) inhibitor, shown to be effective in more than 50% of chronic lymphocytic leukaemia (CLL) patients who relapse or are refractory to previous treatment

10 June 2016

Read full press release »


file

AbbVie announces The Lancet Oncology publication of Phase 2 data showing high overall response rates for Venetoclax in patients with relapsed/refractory chronic lymphocytic leukaemia with 17p deletion

16 May 2016

Read full press release »


file

Scottish Medicines Consortium (SMC) accepts Humira® (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland

9 May 2016

  • Hidradenitis suppurativa (HS, also known as acne inversa), affects around 1% of the population, representing over 50,000 people in Scotland


Read full press release »


file

NICE recommends Humira® (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales

6 May 2016

  • Hidradenitis suppurativa (HS, also known as acne inversa), is a painful skin condition which affects an estimated 977,000 people in the UK


Read full press release »


file

AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-530 for Hepatitis C Genotypes 1-6

16 April 2016

  • 97-98 percent SVR12 achieved with eight weeks of ABT-493 and ABT-530 in genotypes 1-3 hepatitis C virus patients without cirrhosis in SURVEYOR-1 and 2 studies
  • 100 percent SVR12 achieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A) new to therapy
  • 100 percent SVR12 achieved with 12 weeks of treatment in genotypes 4-6 patients without cirrhosis; eight-week duration investigated in this ongoing study


Read full press release »


file

AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry

15 April 2016

  • VIEKIRAX and EXVIERA achieved 96 percent SVR12 in genotype 1 and 100 percent in genotype 4 chronic hepatitis C virus infected patients in a large ongoing real-world study
  • Data support findings from previous HCV Phase 3 clinical trials with VIEKIRAX and EXVIERA in these patient populations
  • Treated patients had a low rate of discontinuation due to adverse events (1.5 percent)


Read full press release »


file

AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals

15 April 2016

  • 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis
  • 91 percent achieved SVR12 with RBV in the primary intent-to-treat analysis; 86 percent achieved SVR12 without RBV


Read full press release »


file

AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients

14 April 2016

  • 100 percent of genotype 1b patients, who received VIEKIRAX + EXVIERA without ribavirin for 12 weeks, achieved SVR12 in a post-hoc analysis no matter whether baseline NS5A RAVs were present
  • 97 percent of genotype 1a patients, both with or without baseline NS5A RAVs, who received the regimen with RBV achieved SVR12


Read full press release »


file

AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Paediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn’s Disease

7 April 2016

  • Paediatric Crohn’s disease is a chronic, inflammatory condition of the gastrointestinal tract that can have a substantial physical and psycho-social impact.


Read full press release »


   

AbbVie thought leadership in Pharmaceutical Market Europe

8 March 2016

Dr Olivia Kessel, UK Director of AbbVie Care, talks about how AbbVIe Care is putting patients at the centre and why this is good news for everyone.

Read full article »

     

file

AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis (Child-Pugh A) in Europe

26 February 2016

  • EU label expansion supported by high cure rates shown in TURQUOISE-III study, a dedicated Phase 3b study of VIEKIRAX + EXVIERA without ribavirin for 12 weeks.
  • 100 percent SVR12 (n=60/60) achieved in genotype 1b patients with compensated cirrhosis (Child-Pugh A); no patients discontinued treatment due to adverse events


Read full press release »


file

AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukaemia (AML)

26 February 2016

  • FDA also recently granted venetoclax Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) for the treatment of patients with AML
  • AML is the most common type of acute leukaemia in adults


Read full press release »


file

NHS England and NHS Wales must now fund AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) +/- EXVIERA® (dasabuvir tablets) when prescribed to adults with genotype 1 or 4 chronic hepatitis C

23 February 2016

  • VIEKIRAX® +/- EXVIERA® is the only interferon-free direct-acting antiviral (DAA) regimen with unrestricted reimbursement across all genotype 1 and genotype 4 patient populations within its marketing authorisation
  • Hospitals in England and Wales are now legally required to fund VIEKIRAX® +/- EXVIERA® for genotype 1 and genotype 4 patients, when prescribed by clinicians


Read full press release »


file

More people living with severe chronic inflammatory back pain to be given access to biological treatments, including AbbVie's Humira (Adalimumab)

2 February 2016

  • Expanded recommendations now include an additional type of chronic inflammatory back pain meaning more people will have access to biological treatments
  • Chronic inflammatory back pain is usually diagnosed in young adults and can affect sleep, everyday activities and professional life, sometimes leading to patients having to leave work entirely
  • It is essential that patients are diagnosed early and receive the right treatment to help prevent irreversible damage to the spine


Read full press release »


smartcare

It’s good to talk – Doctor-patient trial shows promise

13 January 2016

The “Smart Care” series from Euronews, which is the largest pan-European news channel available in 400 million households across the word, looks at sustainable solutions to support the future of healthcare. In January 2016, the programme featured a Shared Decision Making tool that AbbVie is partnering on with the University of Cardiff to help improve patient outcomes and get people back to work and being productive, relieving the burden on the UK health system.

Watch the Euronews video report here.  


file

NICE expands recommendations including AbbVie's Humira (Adalimumab), as a treatment option, offering patients living with juvenile idiopathic arthritis more choice

16 December 2016

  • New recommendations on Juvenile Idiopathic Arthritis (JIA) means that people with the disease should have access to a wider choice of biological treatments
  • JIA is a painful condition diagnosed in children, affecting their life at home and school and impacting the while family
  • Access to treatment is critical for people with JIA in order to reduce joint damage and prevent lasting impacts of the disease


Read full press release »


natasha-kaplinsky

AbbVie addresses the sustainable healthcare challenges of our time

2 December 2015

In 2013 AbbVie, in partnership with the College of Medicine set up a Steering Group to develop a roadmap to delivering sustainable healthcare in the UK. In December 2015, the Steering Group published a one year on report and convened an inaugural conference to bring key healthcare stakeholders together to discuss solutions to the healthcare challenges of our time. The conference was covered by ITN, who produced a special video report, hosted by Natasha Kaplinsky.

Watch the video here.


file

The National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) EXVIERA® (dasabuvir tablets) for the Treatment of Adults with Chronic Hepatitis C in England and Wales

16 October 2015

  • VIEKIRAX + EXVIERA confirmed as cost-effective treatment for adults with genotype 1 chronic hepatitis C virus (HCV) infection, including those with HIV/HCV co-infection, in NICE Final
  • VIEKIRAX also confirmed as cost-effective treatment option for all adults with genotype 4 chronic HCV infection, including those with HIV/HCV co-infection
  • An estimated 214,000 people in the UK are chronically infected with hepatitis C, of which only an estimated 3 percent receive treatment in England each year


Read full press release »


file

New NHS England Clinical Commissioning Policy Statement recommends AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA® (dasabuvir) as an option for the treatment of chronic hepatitis C in patients with cirrhosis

10 June 2015

  • NHS England’s Clinical Priorities Advisory Group (CPAG) for Infectious Diseases recommends adoption of a commissioning policy for the treatment of chronic hepatitis C in patients with cirrhosis and advanced liver disease
  • More than 200,000 people in the UK are chronically infected with hepatitis C1, of which only an estimated 3% are treated each year, despite the advent of treatments that can offer viral elimination1


Read full press release »


file

AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA® (dasabuvir) accepted for use within NHS Scotland

8 June 2015

Scottish Medicines Consortium accepts VIEKIRAX® and EXVIERA® for the treatment of adults in Scotland with genotype 1 and genotype 4 chronic hepatitis C virus infection

Read full press release »


file

AbbVie’s HUMIRA® (Adalimumab) Approved by European Commission to Treat Children and Adolescents with Severe Chronic Plaque Psoriasis

19 April 2015

HUMIRA is the only Biologic Approved in Europe for Children and Adolescents from Four Years of Age

Read full press release »


file

THE EVIDENCE IS THERE. WE NOW NEED TO ACT

19 March 2015

EU, multi-stakeholder group launches recommendations for creating sustainable healthcare systems across Europe. 

Read full press release »


file

AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA ® (dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C

19 January 2015

  • First treatments for chronic hepatitis C to combine three direct-acting antiviral agents to target hepatitis C virus (HCV) at multiple steps in the viral lifecycle
  • VIEKIRAX® and EXVIERA®, with or without ribavirin (RBV), cleared the virus in 97 percent of chronic genotype 1 (GT1) HCV patients and was generally well tolerated
  • AbbVie Care in hepatitis C also launched in the UK to help people maintain motivation, focus and stability while on treatment
     

Read full press release »

Leave the UK site

The Abbvie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Abbvie Internet site that you have requested may be in a language that differs from your country of origin.

The Abbvie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this Abbvie site?

Exit abbvie.co.uk

The product-specific Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The product-specific Internet site that you have requested may not be optimized for your screen size.

Do you wish to continue to this product-specific site?

AXCOR121934c(2) - DECEMBER 2014

Exit abbvie.co.uk

Notice

The “Yes” link below will take you out of AbbVie family of websites

Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?